Last €43.12 EUR
Change Today 0.00 / 0.00%
Volume 0.0
As of 11:50 AM 11/3/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

Lilly Corporate Center

Indianapolis, IN 46285

United States

Phone: 317-276-2000


Eli Lilly and Company discovers, develops, manufactures, and markets products in human pharmaceutical and animal health products. The company’s animal health business, operating through its Elanco division, develops, manufactures, and markets products for both food animals and companion animals. Its products are sold in approximately 120 countries. Products Human Pharmaceutical Products Endocrinology Products The company’s endocrinology products include Humalog, Humalog Mix 75/25, and Humalog Mix 50/50 insulin analogs for the treatment of diabetes; Humulin, human insulin of recombinant DNA origin for the treatment of diabetes; Trajenta, an oral medication for the treatment of type 2 diabetes; Jentadueto, a combination tablet of Trajenta and metformin hydrochloride for use in the treatment of type 2 diabetes; Forteo for the treatment of osteoporosis in postmenopausal women and men at high risk for fracture and for glucocorticoid-induced osteoporosis in men and postmenopausal women; Evista for the prevention and treatment of osteoporosis in postmenopausal women and for the reduction of the risk of invasive breast cancer in postmenopausal women with osteoporosis and postmenopausal women at high risk for invasive breast cancer; Humatrop, for the treatment of human growth hormone deficiency and certain pediatric growth conditions; and Axiron, a topical solution of testosterone, applied by underarm applicator, for replacement therapy in men for certain conditions associated with a deficiency or absence of testosterone. Neuroscience Products The company’s neuroscience products include Cymbalta for the treatment of major depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, and in the U.S. for the management of fibromyalgia and of chronic musculoskeletal pain due to chronic low back pain or chronic pain due to osteoarthritis; Zyprexa for the treatment of schizophrenia, acute mixed or manic episodes associated with bipolar I disorder, and bipolar maintenance; Strattera for the treatment of attention-deficit hyperactivity disorder; Prozac for the treatment of major depressive disorder, obsessive-compulsive disorder, bulimia nervosa, and panic disorder; and Amyvid, a radioactive diagnostic agent approved in the U.S. and the European Union (EU) for positron emission tomography (PET) imaging of beta-amyloid neuritic plaques in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer's disease and other causes of cognitive decline. Oncology Products The company’s oncology products comprise: Alimta for the first-line treatment, in combination with another agent, of advanced non-small cell lung cancer (NSCLC) for patients with non-squamous cell histology; for the second-line treatment of advanced non-squamous NSCLC; as monotherapy for the maintenance treatment of advanced non-squamous NSCLC in patients whose disease has not progressed immediately following chemotherapy treatment; and in combination with another agent, for the treatment of malignant pleural mesothelioma. Erbitux, indicated both as a single agent and with another chemotherapy agent for the treatment of certain types of colorectal cancers; and as a single agent or in combination with radiation therapy for the treatment of certain types of head and neck cancers. Gemzar for the treatment of pancreatic cancer; in combination with other agents, for the treatment of metastatic breast cancer, NSCLC, and advanced or recurrent ovarian cancer; and in the EU for the treatment of bladder cancer. Cardiovascular Products The company’s cardiovascular products include Cialis for the treatment of erectile dysfunction and benign prostatic hyperplasia (BPH); Effient for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndrome who are managed with an artery-opening procedure known as percutaneous coronary intervention (PCI), including patients undergoing angioplasty, atherectomy, or stent placement; ReoPro for use as an adjunct to PCI for the prevention of cardiac ischemic complications; and Adcirca for the treatment of


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LLY:FP €43.12 EUR 0.00

LLY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $47.37 USD -0.24
AbbVie Inc $60.50 USD -0.02
Actavis plc $291.36 USD +1.58
AstraZeneca PLC 4,470 GBp +4.50
Bristol-Myers Squibb Co $60.92 USD -0.54
View Industry Companies

Industry Analysis


Industry Average

Valuation LLY Industry Range
Price/Earnings 31.5x
Price/Sales 3.8x
Price/Book 4.8x
Price/Cash Flow 32.6x
TEV/Sales 3.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ELI LILLY & CO, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at